Intron

iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology

Retrieved on: 
Thursday, February 15, 2024
Biotechnology, CRISPR, Intron, Robot, Bacteriophage, Gene, Plasma protein binding, Mutation, Colorectal cancer, Research, SON

BOSTON, Feb. 14, 2024 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that New Drug Part has secured a potent anti-cancer candidate, PHAGERIA®, with broad antimicrobial activity against ETBF (Enterotoxigenic B. fragilis), a harmful microbe associated with colorectal cancer.

Key Points: 
  • iNtRON stated that following the proprietary development of the Robot Bacteriophage 2nd generation technology, additional in-vitro evolution technology was applied.
  • The Company previously secured the technology to customize and edit bacteriophage genomes as desired using tailored CRISPR/Cas technology and Random Transposon Mutagenesis in 2022.
  • Recently, the Company has advanced this technology further to develop a more potent anti-cancer candidate, PHAGERIA®.
  • This achievement is significant as it is the first instance of applying in-vitro Evolution technology to ETBF bacteriophages, demonstrating the excellence of the bacteriophage gene editing technology (CRISPR/Cas) and Robotic Bacteriophage improvement platform technology of the Company.

Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent

Retrieved on: 
Tuesday, October 31, 2023
KOSDAQ, Trial of the century, South Korea, MSSA, Bacteriophage, Biofilm, Intron, Gram-positive bacteria, Infection, Virus, Exercise, Biotechnology, A-DNA, Antimalarial medication, MRSA, LR, Bacteria, Korea, Patient, Death, Pharmaceutical industry, Vaccine, Basel, Allschwil

Tonabacase is a potential first-in-class clinical-stage antibacterial of the endolysin class.

Key Points: 
  • Tonabacase is a potential first-in-class clinical-stage antibacterial of the endolysin class.
  • Over the course of 2024, Basilea will investigate various hypotheses in a number of preclinical studies to determine the optimal future clinical development program for tonabacase.
  • Upon successful completion of the preclinical evaluation phase, Basilea will have the exclusive option to license tonabacase for further clinical development and commercialization.
  • This transaction has no impact on Basilea’s financial guidance for 2023, provided on August 15, 2023.

iNtRON, Executes Evaluation License and Option Agreement for SAL200

Retrieved on: 
Tuesday, October 31, 2023
Infection, US, Intron, Basel, Biotechnology, Probability, NDA, Fungal infection, Pharmaceutical industry, Allschwil

BOSTON and SEOUL, South Korea, Oct. 30, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today that they have signed an "EVALUATION LICENSE AND OPTION AGREEMENT" with Basilea Pharmaceutica Ltd, Allschwil ("Basilea"), granting Basilea the option to enter into an exclusive license agreement for the antibacterial bio-drug SAL200 (Tonabacase).

Key Points: 
  • BOSTON and SEOUL, South Korea, Oct. 30, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today that they have signed an "EVALUATION LICENSE AND OPTION AGREEMENT" with Basilea Pharmaceutica Ltd, Allschwil ("Basilea"), granting Basilea the option to enter into an exclusive license agreement for the antibacterial bio-drug SAL200 (Tonabacase).
  • iNtRON will receive an initial upfront payment upon the execution of this agreement and will receive an additional payment upon Basilea exercising the option to negotiate an exclusive license agreement after the completion of the evaluation test, which can last up to one year.
  • Certain essential terms of the exclusive license agreement have been pre-agreed upon along with the current agreement.
  • iNtRON has been actively discussing the exclusive license agreement with Basilea, who showed keen interest in SAL200.

AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

Retrieved on: 
Monday, June 12, 2023
CIPC, TNBC, Pancreatic cancer, Roswell Park Comprehensive Cancer Center, AIM, University, Therapy, University of Nebraska Medical Center, TLR3, Methods used to study memory, Intron, LAPC, RNA, Number, Survival, Clinical trial, SITC, Celecoxib, Nebraska Medicine, Viral, Research, Neoplasm, Biomarker, FOLFIRINOX, ClinicalTrials.gov, Doctor of Philosophy, PCR, South African patent system, Pancreas, Erasmus MC, Cancer, Publication, Professor, MD, DSM-IV codes, Blood, Annual general meeting, Peripheral, Roswell, B cell, NYSE, Safety, Vaccine, Pharmaceutical industry, Nursing, Ebola, Rintatolimod, Patient

Ampligen continues to demonstrate significant potential across multiple types of cancers, immune disorders and viral diseases.

Key Points: 
  • Ampligen continues to demonstrate significant potential across multiple types of cancers, immune disorders and viral diseases.
  • AMP-270 is expected to enroll approximately 90 subjects in up to 30 centers across the United States and Europe.
  • The Company is recruiting patients for its AMP-270 Phase 2 study of Ampligen as a therapy for LAPC.
  • The lead site at the University of Nebraska Medical Center is now open and actively working to enroll patients.

New England Biolabs® Chief Scientific Officer Elected to National Academy of Sciences

Retrieved on: 
Thursday, June 8, 2023
Molecular biology, Nobel Prize, DNA, National academy, NAS, CSO, Parasitology, RNA, Science, Rich, Publication, Genome, Humble Oil, NEB, 2021 Nobel Prize in Physiology or Medicine, Intron, New England Biolabs, Pharmaceutical industry, Research, Medicine, Physiology

IPSWICH, Mass., June 8, 2023 /PRNewswire/ -- Today, New England Biolabs (NEB®) announced that Sir Richard Roberts, Nobel Prize winner and Chief Scientific Officer (CSO) at NEB, has been inducted into the National Academy of Sciences (NAS), a private, nonprofit society of distinguished scientific scholars committed to furthering science and scientific research in the USA. Scientists elected to NAS are selected by their peers based on their exceptional contributions in research.

Key Points: 
  • IPSWICH, Mass., June 8, 2023 /PRNewswire/ -- Today, New England Biolabs (NEB®) announced that Sir Richard Roberts, Nobel Prize winner and Chief Scientific Officer (CSO) at NEB, has been inducted into the National Academy of Sciences (NAS), a private, nonprofit society of distinguished scientific scholars committed to furthering science and scientific research in the USA.
  • Scientists elected to NAS are selected by their peers based on their exceptional contributions in research.
  • "I've been very fortunate to witness my research contribute to our evolving understanding of the life sciences over the course of my career," said Roberts.
  • He served as a consultant and chairman of NEB's scientific advisory board from 1975 and joined the company as CSO in 1992.

iNtRON identifies Prophage and Jamphage in the Pancreatic cancer related Microbiome

Retrieved on: 
Tuesday, May 30, 2023
SON, Survivor, Alkalihalobacillus clausii, IR, Biotechnology, Prevalence, Pancreatic cancer, Bacteriophage, Drug discovery, Survival, Open reading frame, Mode of action, Cancer, STS, Radio spectrum, Research, DSM-IV codes, Colorectal cancer, Acquisition, Parkinson's disease, Patient, Pancreas, Immune system, Intron, Mode, Growth, Bacteria, Mall of America, Recurrence, LTS, Alzheimer's disease, Genome, Vaccine, Pharmaceutical industry, Large intestine, Prophage

BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today the identification of Prophage and (non-) ORF-Jamphage from the microbiome frequently observed in long-term Pancreatic cancer survivors.

Key Points: 
  • BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today the identification of Prophage and (non-) ORF-Jamphage from the microbiome frequently observed in long-term Pancreatic cancer survivors.
  • The ultimate goal is to develop phage-based immunotherapeutics capable of treating a range of immune disorders including cancer.
  • The primary focus of the company lies in Colorectal cancer and Pancreatic cancer.
  • Alkalihalobacillus clausii has been identified as a representative microbiome, and iNtRON has obtained the strain and confirmed the presence of Prophage and Jamphage through the genomic analysis.

RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors

Retrieved on: 
Thursday, April 27, 2023
Oncology, Health, Medical Devices, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Pancreatic cancer, PTC Therapeutics, University, Temozolomide, SPARC, Intron, Schering-Plough, LAPC, Leukemia, PTC, New Drug Application, NDA, TAP, LLS, Associate, Protein-bound paclitaxel, Warburg Pincus, National Cancer Institute, Infliximab, Interferon alfa-2b, Geron Corporation, Patient, PH, Cancer, Merck, FDA, SR, Therapy, Safety, Weill Cornell Medicine, Pharmaceutical industry, MD, Medicine

Dr. Spiegel brings more than 40 years of biopharmaceutical experience to RenovoRx’s Board.

Key Points: 
  • Dr. Spiegel brings more than 40 years of biopharmaceutical experience to RenovoRx’s Board.
  • While at Schering-Plough, he served as Sr. Vice President of Worldwide Clinical Research and Chief Medical Officer.
  • Dr. Spiegel completed his Medical Oncology fellowship at the National Cancer Institute and received his MD from the University of Pennsylvania.
  • Our team is also engaging with worldwide regulatory agencies and identifying new indications and combination products utilizing our therapy platform, RenovoTAMP®.”

iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model.

Retrieved on: 
Tuesday, April 4, 2023
SON, CIN, Intellectual property, Biotechnology, Genetic engineering, CRC, CIMP, Phageome, Microsatellite instability, Bacteriophage, Cancer, Ageing, BFT, Statistics, Research, Attention, Colon, Patient, Organoid, Colorectal cancer, Bacteroides fragilis, MSI, Intron, CpG, Recurrence, Smoking, Chromosome instability, Metastasis, Pharmaceutical industry, Vaccine

BOSTON and SEOUL, South Korea, April 3, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today that iNtRON has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model.

Key Points: 
  • BOSTON and SEOUL, South Korea, April 3, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today that iNtRON has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model.
  • P18-BE3CRC is a drug candidate of PHAGERIA® platform technology, which is for the development and commercialization of bacteriophage-based drugs (Phageome API) effective for cancer control.
  • As comparing the cases with or without administering PHAGERIA® candidate, it was confirmed that administering PHAGERIA® candidate significantly inhibited tumorigenesis.
  • Mr. YOON, Kyung-won, CEO of iNtRON said that "We will accelerate follow-up research and development through partnerships with global companies.

ARway Secures Multiple New SDK Deals to Drive Growth in $44B Indoor Positioning and Navigation Market

Retrieved on: 
Thursday, March 30, 2023
Augmented reality, CSE, Intron, API, Iveco Bus, Innovation system, IOS, FSE, Android, DQ, Museum, Orangi Pilot Project, OTC, SDK, E65, MENA, AR, Education, Software development kit, Online shopping, University

Since the SDK was released on January 31, 2023 the Company has been experiencing a wave of demand from resellers, enterprise corporations and brands.

Key Points: 
  • Since the SDK was released on January 31, 2023 the Company has been experiencing a wave of demand from resellers, enterprise corporations and brands.
  • These SDK deals range in size from $9,000-$15,000 based on the usage of the platform, and are within various industries representing a wide range of use cases for ARway technology.
  • Finally, a pricing tier for the Education market has been introduced that will make campus-wide deployment of Augmented Reality experiences more accessible.
  • The Company is planning to introduce features and capabilities, unique to each market segment, over time to complement these pricing tiers and further differentiate its offerings.

Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients

Retrieved on: 
Friday, December 9, 2022
Gene expression, Security (finance), Exact Sciences (company), Prognosis, Recurrence, Swedish, Breast, University of Gothenburg, Diagnosis, Genomic Health, Oncotype (Denmark), Princess, Patient, DNA, Omission, Cancer, Meta-analysis, Annual report, Breast cancer, Exact sciences, Princess Margaret Hospital, Guideline, Risk, News, University, Radiation, Intron, Gene, RNA, Medical imaging

The meta-analysis of three independent, randomized clinical trials identified which early-stage breast cancer patients benefited from radiotherapy after breast-conserving surgery.

Key Points: 
  • The meta-analysis of three independent, randomized clinical trials identified which early-stage breast cancer patients benefited from radiotherapy after breast-conserving surgery.
  • "Exact Sciences' POLAR signature addresses a significant clinical need for those with early-stage, hormone receptor positive breast cancer, identifying which patients may benefit from radiotherapy and which may not," said Rick Baehner, M.D., chief medical officer of Precision Oncology at Exact Sciences.
  • These data are a critical step toward providing patients with a new tool to help ensure better breast cancer treatment decisions."
  • In breast cancer, the Oncotype DX Breast Recurrence Scoretest is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.